Published in Sci Rep on January 04, 2017
Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation (2006) 4.98
A model for human ventricular tissue. Am J Physiol Heart Circ Physiol (2003) 4.91
International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist (2005) 4.86
Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol (2011) 3.21
Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem (1996) 2.95
Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther (2012) 2.77
Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet (2011) 2.67
Electrophysiologic characteristics of cells spanning the left ventricular wall of human heart: evidence for presence of M cells. J Am Coll Cardiol (1995) 2.42
Gene expression in distinct regions of the heart. Lancet (2000) 2.35
Tricyclic antidepressant overdose: a review. Emerg Med J (2001) 2.10
Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci (2005) 1.95
The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol (2009) 1.88
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK. CPT Pharmacometrics Syst Pharmacol (2015) 1.88
Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci (2006) 1.85
Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J (2013) 1.77
The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J (1984) 1.49
Cell model for efficient simulation of wave propagation in human ventricular tissue under normal and pathological conditions. Phys Med Biol (2006) 1.30
Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol (2013) 1.27
Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos (2007) 1.25
Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics (2004) 1.20
The simcyp population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacol (2013) 1.11
Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov (2016) 1.01
Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. Curr Pharmacol Rep (2016) 0.98
Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. J Pharmacokinet Pharmacodyn (2001) 0.96
Paralytic shellfish poisoning: post-mortem analysis of tissue and body fluid samples from human victims in the Patagonia fjords. Toxicon (2004) 0.95
The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions. Am J Med (2005) 0.95
Pharmacokinetic parameter prediction from drug structure using artificial neural networks. Int J Pharm (2004) 0.95
Coronary blood flow in man. Prog Cardiovasc Dis (1976) 0.93
Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther (1983) 0.90
Evaluation of right ventricular volume and mass using retrospective ECG-gated cardiac multidetector computed tomography: comparison with first-pass radionuclide angiography. Eur Radiol (2005) 0.90
The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn (2013) 0.89
Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos (2006) 0.87
Plasma binding variations of amitriptyline and nortriptyline. Clin Pharmacol Ther (1982) 0.84
Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol (1997) 0.84
Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs. CPT Pharmacometrics Syst Pharmacol (2015) 0.84
Physiology of pericardial fluid production and drainage. Front Physiol (2015) 0.83
Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. Eur J Pharm Sci (2011) 0.82
The effects of six antipsychotic agents on QTc--an attempt to mimic clinical trial through simulation including variability in the population. Comput Biol Med (2014) 0.82
Intravenous lipid emulsion entraps amitriptyline into plasma and can lower its brain concentration--an experimental intoxication study in pigs. Basic Clin Pharmacol Toxicol (2013) 0.81
In vitro-in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discov Today (2013) 0.81
Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol (2001) 0.80
QTc modification after risperidone administration--insight into the mechanism of action with use of the modeling and simulation at the population level approach. Toxicol Mech Methods (2015) 0.80
Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One (2010) 0.80
Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making. CPT Pharmacometrics Syst Pharmacol (2015) 0.80
Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. Eur J Pharm Sci (2016) 0.79
Intrapericardial delivery of amiodarone and sotalol: atrial transmural drug distribution and electrophysiological effects. J Cardiovasc Pharmacol (2009) 0.79
Determination of free fractions of tricyclic antidepressants. Naunyn Schmiedebergs Arch Pharmacol (1984) 0.78
Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline. Int Clin Psychopharmacol (1986) 0.77
Interindividual differences in amitriptyline demethylation. Clin Pharmacol Ther (1980) 0.77
Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol (1985) 0.77
Plasma vs heart tissue concentration in humans - literature data analysis of drugs distribution. Biopharm Drug Dispos (2015) 0.76
Pericardial fluid as an alternative specimen to blood for postmortem toxicological analyses. Leg Med (Tokyo) (1999) 0.76
Possible markers for postmortem drug redistribution. J Forensic Sci (1997) 0.76
Plasma protein binding of perazine and amitriptyline in psychiatric patients. Eur J Clin Pharmacol (1982) 0.76
Myocardial drug distribution generated from local epicardial application: potential impact of cardiac capillary perfusion in a swine model using epinephrine. J Control Release (2014) 0.76
Binding of amitriptyline and nortriptyline in plasma determined from their equilibrium distributions between red cells and plasma, and between red cells and buffer solution. Psychopharmacology (Berl) (1981) 0.76
Quantification of 16 QT-prolonging Drugs and Metabolites in Human Postmortem Blood and Cardiac Tissue Using UPLC-MS-MS. J Anal Toxicol (2016) 0.76
Blood/plasma distribution ratios of psychotropic drugs. Clin Chem (1980) 0.76
Postmortem distribution of tramadol, amitriptyline, and their metabolites in a suicidal overdose. J Anal Toxicol (2005) 0.76
Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations. Curr Pharmacol Rep (2016) 0.75